famotidine has been researched along with Hospital-Acquired Condition in 2 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, YJ | 1 |
| Cheon, JH | 2 |
| Lee, SK | 1 |
| Kim, JH | 1 |
| Lee, YC | 1 |
| Ye, BD | 1 |
| Choi, KD | 1 |
| Kim, SG | 1 |
| Kim, JS | 1 |
| Jung, HC | 1 |
| Song, IS | 1 |
2 trials available for famotidine and Hospital-Acquired Condition
| Article | Year |
|---|---|
Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Famotidine; | 2010 |
Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial.
Topics: Anti-Ulcer Agents; Famotidine; Female; Gastric Mucosa; Gastrointestinal Hemorrhage; Gastroscopy; Hum | 2006 |